Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): SonoVue, sulphur hexafluoride, Date of authorisation: 26/03/2001, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Date of authorisation: 25/06/2020, Revision: 10, Status: Authorised

Agenda of the PRAC meeting 24 - 27 November 2025

Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Hizentra, human normal immunoglobulin (SCIg), Date of authorisation: 14/04/2011, Revision: 28, Status: Authorised

PSUSA/00002510/202501